LXRepair brings in €1.1 million

Startup LXRepair, a CEA spinoff founded in 2013, has just raised €1.1 million in capital from investors Kreaxi, CEA-Investissement, XPAND Investissement Ltd., Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane participations, and private individuals. LXRepair will use the funds to complete clinical proof-of-concept studies in oncology, obtain the CE mark for its innovative DNA repair measurement systems, and boost its international development strategy.
The company’s enzyme assay kit, which leverages research patented by INAC, identifies markers that help predict a patient’s response—whether it is toxicity or resistance—to cancer therapies. The company’s first kit, Glyco-SPOT, already on the market, is used for research only.

Contact: sylvie.sauvaigo@lxrepair.com

Facebook

Twitter